Beta Blockers for the Prevention of Acute Exacerbations of COPD
Abstract
We are conducting a randomized, placebo-controlled trial to definitively assess the impact of metoprolol succinate on the rate of COPD exacerbations. This is a multicenter, placebo-controlled, double-blind, prospective randomized trial that will enroll 1028 patients with at least moderately severe COPD over a 3-year period. Major activities for this reporting period have centered on contracting, regulatory approvals, training, site initiation and enrollment at clinical sites. Upon execution of contracts and IRB approvals enrollment has been steadily increasing. The monthly enrollment goal is 28.5 across all sites, with each site enrolling an average of 2-3 participants per month. Several sites have met and exceeded this goal in August and September and we expect this trend to continue.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2016
- Accession Number
- AD1034632
Entities
People
- Mark T Dransfield
Organizations
- University of Alabama at Birmingham